In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
 
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

Testimonials
  Through its 'Corporate Partnership Program', Bioscience Valuation has provided exceptional support in the transformation of our business model. BSV's evidence-based assessments proved invaluable for our strategic decision making as well as for preparing our corporate transactions.

Peter Llewellyn-Davies, CFO/CBO
Medigene AG

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Bioscience Valuation's Downloads

Platform Life Sciences Biotechnology 2020 Volume 22

The recent US-NASDAQ-100 index is at 8.1, clearly above the long-term average of 4.1. In order to compete, European biotechs should elaborate on their value propositions and invest in capital market communication. Work with us on your value story and let us demonstrate asset value.

Download the paper 'Platform Life Sciences' Biotechnology 2020 Volume 22



Creating unique equity stories

Bioscience Valuation earned significant reputation for quantitative assessments of biotech/pharma projects and for creating unique equity stories.

Download the paper 'Creating unique equity stories' and get to know our approach that has been successful to attract potential strategic and financial investors.



Be Empowered By Our Valuation Models Flyer

Excel with your own project valuation and financial deal term assessments.

Bioscience Valuation’s state-of-the-art valuation model facilitates your performing your own valuation assessments and sensitivity analyses, be it for a piece of technology, project, product or the company. Download our flyer, Be Empowered By Our Valuation Models.



Optimize Your Drug Portfolio Flyer

Partner with us, a global leader in evidence-based evaluations.

Download our flyer, Optimize Your Drug Portfolio to see how you can maximize your pipeline value, solidly valuate each individual asset’s development strategy and commercial potential including associated risks, or perform a best-practice systematic portfolio review.



Bioscience Valuation Company Brochure

We invite you to download our informative Bioscience Valuation Brochure:

Read what our Founder & Managing Director, Dr. Joachim Greuel, has to say about making R&D and commercial risks identifiable and manageable.

Find out about how our wide range of services, especially the Bioscience Valuation Approach, can become useful and meaningful for you. Read how highly our clients think of us.



Bioscience Valuation Company Brochure

If you are particularly interested in Achieving High-Value Deals, our flyer with this focus is just right for you. You may find some ready answers and be inspired to check with us.



Outsourcing License Assessments

Have you considered the benefits of Outsourcing License Assessments? This flyer introduces us, a global leader, as your partner for evidence-based scientific, commercial and value evaluations. We would be happy to discuss with you in person.






This website uses cookies to ensure you get the best experience on our website.
Privacy Policy